Endocrine Abstracts

Serum ALT concentrations give some insight into liver fat accumulation and relate to metabolic syndrome: values >29 IU/L double risk of type 2 diabetes independent of other risk predictors. Women with PCOS are at increased risk of diabetes and CVD whereas metformin treatment modulates the progress of metabolic syndrome. Consequently, we investigated the effects of protracted metformin treatment on circulating ALT in obese women with PCOS.Metformin tr...

Serum ALT concentrations give some insight into liver fat accumulation and relate to metabolic syndrome: values>29 IU/L double risk of type 2 diabetes independent of other risk predictors. Women with PCOS are at increased risk of diabetes and CVD whereas metformin treatment modulates the progress of metabolic syndrome. Consequently, we investigated the effects of protracted metformin treatment on circulating ALT in obese women with PCOS.Methods<p...

Introduction: Polycystic ovary syndrome (PCOS) is associated with insulin resistance and hyperandrogenism. In many cases this leads to hirsutism, for which a common treatment is combined anti-androgen and estrogen therapy (Dianette; Schering Ltd). The insulin sensitising agent metformin has been reported to reduce hyperandrogenism in women with PCOS.The aim of this study was to compare the clinical efficacy of Dianette with metformin (Glucophage; Merck, 500mgs tds) in the ...

Background: Use of metformin in women with polycystic ovary syndrome (PCOS) is becoming increasingly accepted and widespread but clinical practice is ahead of the evidence.Methods: We extracted results from the seven published studies of metformin use in PCOS that include control elements quantifiably similar to the experimental arm. We also restricted our analysis to the studies with a systematic longitudinal examination of ovulatory function and metabolic parameters....

Metformin treatment of women with PCOS has been shown to improve ovarian function, reduce hyperandrogenicity and induce weight loss. The aim of this prospective study was to investigate the nature of the weight loss in obese women with PCOS, using 2 dose regimes.Methods: Obese (body mass index [BMI] > 29 kilograms /m2) women with PCOS (n = 44) were recruited to the study, and randomised to receive either 1500mg metformin daily (n = 22), or ...

Hirsutism in women with polycystic ovary syndrome (PCOS) is associated with hyperandrogenism and insulin resistance. The insulin sensitising agent metformin can reduce hyperandrogenism in women with PCOS. Conventional treatment for hirsutism in such women is combined anti-androgen and estrogen (Dianette; Schering Ltd). The aim of this study was to compare the clinical efficacy of Dianette with metformin (Glucophage; Merck, 500mgs tds) in the treatment of hirsutism in women wit...

Mullerian Inhibiting Substance (MIS) is a member of the transforming growth factor beta superfamily of growth factors, which causes regression of the Mullerian duct in male embryos, and is believed to act in a paracrine fashion after birth to regulate granulosa cell and oocyte function. MIS appears to be an important regulator of primordial follicle recruitment, and is also capable suppressing androgen production. Abnormal ovarian function is implicit in polycystic ovary syndr...